MedTrace Logo

National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood

NCT03183401 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2017-06-21

No results posted yet for this study

Summary

The DENACAPST programme represents an important initiative to provide near nation-wide roll-out of an important cancer surveillance program for childhood cancer survivors. The program is based on internationally recognized standards in cancer surveillance, which were developed by the International Guideline Harmonization Group (IGHG) with support of all relevant stakeholders in cancer survivorship research and clinical work in Europe, Canada and the United States and recognized French recommendations about breast screening for women at high risk of cancer.

With this programme, French centers organized themselves to provide to childhood cancer survivors adequate medical attention, which includes close medical surveillance for breast/thyroid cancer where appropriate, based on adequate risk stratification.

The aim of the study is to analyze if the recommendations about breast and thyroid cancer screening are followed in this population and secondly to provide more informations about these second cancers and about the screening.

Conditions

  • Early Detection of Cancer

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • charlotte demoor-goldschmidt · Institut National de la Santé Et de la Recherche Médicale, France

  • florent de vathaire · Institut National de la Santé Et de la Recherche Médicale, France

  • gerard michel · chu

  • pascal auquier · medical university of Marseille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-09
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03183401 on ClinicalTrials.gov